Key Milestones

Home page | Contact us | Cephalon websites | Site map

SEARCH

The global success story

The expansion in EMEA

A local presence

Research & Development

Key milestones

1987	Cephalon, Inc. founded by Frank Baldino, Jr., Ph.D
1991	Initial Public Offering (IPO) on the NASDAQ
1993	Cephalon establishes a European presence in the United Kingdom and Ireland
1994	MODIODAL^® (modafinil) launch in France, first in a new class of wakefulness promoting agents
1998	PROVIGIL^® (modafinil) approved in the UK
2000	Acquisition of ACTIQ^® (fentany citrate) for the treatment of BreakThrough cancer Pain (BTcP)
2001	Acquisition of the French pharmaceutical company Laboratoires L.Lafon
2004	Acquisition of NAXY^® and MONONAXY^® (clarithromycin) exclusive rights for the French market
2005	Acquisition of TRISENOX^®(arsenic trioxide) for haematological malgnancies Creation of European Headquarters in Maisons-Alfort, near Paris, France Acquisition of Zeneus Pharma Ltd, a European company specialised in Oncology
2007	Nevers Lyoc^®II Grand Opening
2008	European Commission marketing approval for EFFENTORA^® (fentanyl) in EU 27 member states
2009	Launch of EFFENTORA^® (fentanyl) in Europe
2010	Agreement to acquire Mepha AG, a Swiss branded generics company

Print